Coverage
Filings
Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.
| 21 Nov 2024 |
| Genmab Announces Financial Results for the First Nine Months of 2024 | 6 Nov 2024 |
| Genmab to Showcase Strength and Breadth of Comprehensive Epcoritamab-bysp Development Program at 2024 American Society of Hematology (ASH) Annual Meeting | 5 Nov 2024 |
| Genmab to Present at Jefferies London Healthcare Conference | 5 Nov 2024 |
| Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2024 | 15 Oct 2024 |
| Major Shareholder Announcement | 4 Oct 2024 |